PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
R&D reduction while CRVO shows 5.59% growth. Joel Greenblatt would examine competitive risk.
-16.18%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
7.12%
Other expenses growth less than half of CRVO's 100.00%. David Dodd would verify if advantage is sustainable.
-22.68%
Operating expenses reduction while CRVO shows 251.41% growth. Joel Greenblatt would examine advantage.
-22.68%
Total costs reduction while CRVO shows 15.98% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
7.12%
D&A growth while CRVO reduces D&A. John Neff would investigate differences.
22.73%
EBITDA growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
22.68%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
26.92%
Other expenses growth while CRVO reduces costs. John Neff would investigate differences.
22.99%
Pre-tax income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense change of 100.00% while CRVO maintains burden. Bruce Berkowitz would investigate strategy.
22.99%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
38.32%
EPS growth while CRVO declines. John Neff would investigate advantages.
38.32%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
24.80%
Share count reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.
24.80%
Diluted share reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.